Last reviewed · How we verify
GSK2269557 100 MCG
At a glance
| Generic name | GSK2269557 100 MCG |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Diarrhoea
- Gastroenteritis
- Nasopharyngitis
- Oral herpes
- Headache
- Cough
- Arthralgia
- Lacrimation increased
- Dry mouth
- Toothache
- Catheter site haematoma
- Vessel puncture site inflammation
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients (PHASE2)
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects (PHASE1)
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects (PHASE1)
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2269557 100 MCG CI brief — competitive landscape report
- GSK2269557 100 MCG updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI